Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2012 (2012), Article ID 721721, 7 pages
http://dx.doi.org/10.1155/2012/721721
Research Article

Schizandrin, an Antioxidant Lignan from Schisandra chinensis, Ameliorates Aβ1–42-Induced Memory Impairment in Mice

1Department of Pharmacognosy, Shenyang Pharmaceutical University, Shenyang 110016, China
2National Population and Family Planning Key Laboratory of Contraceptives Drugs & Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China
3Pharmacy College, Jinan University, Guangzhou 510632, China

Received 7 March 2012; Revised 14 May 2012; Accepted 14 May 2012

Academic Editor: David Vauzour

Copyright © 2012 Di Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. T. Francis, A. M. Palmer, M. Snape, and G. K. Wilcock, “The cholinergic hypothesis of Alzheimer's disease: a review of progress,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 2, pp. 137–147, 1999. View at Google Scholar · View at Scopus
  2. D. J. Selkoe, “The molecular pathology of Alzheimer's disease,” Neuron, vol. 6, no. 4, pp. 487–498, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Schubert, C. Behl, R. Lesley et al., “Amyloid peptides are toxic via a common oxidative mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 6, pp. 1989–1993, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. B. A. Yankner, “Mechanisms of neuronal degeneration in Alzheimer's disease,” Neuron, vol. 16, no. 5, pp. 921–932, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Inglis, “The tolerability and safety of cholinesterase inhibitors in the treatment of dementia,” International Journal of Clinical Practice, Supplement, no. 127, pp. 45–63, 2002. View at Google Scholar · View at Scopus
  6. R. S. Doody, “Clinical profile of donepezil in the treatment of Alzheimer's disease,” Gerontology, vol. 45, 1, pp. 23–32, 1999. View at Google Scholar · View at Scopus
  7. L. Chiu and S. H. Yang, “Fructus Schisandrae: possesses anti-cancer and anti-aging activities,” Gansu Medical Journal, vol. 11, p. 288, 1992. View at Google Scholar
  8. J. L. Hancke, R. A. Burgos, and F. Ahumada, “Schisandra chinensis (Turcz.) Baill,” Fitoterapia, vol. 70, no. 5, pp. 451–471, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. M. T. Hsieh, C. R. Wu, W. H. Wang, and L. W. Lin, “The ameliorating effect of the water layer of Fructus schisandrae on cycloheximide-induced amnesia in rats: interaction with drugs acting at neurotransmitter receptors,” Pharmacological Research, vol. 43, no. 1, pp. 17–22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Egashira, K. Kurauchi, K. Iwasaki et al., “Schizandrin reverses memory impairment in rats,” Phytotherapy Research, vol. 22, no. 1, pp. 49–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Zhang, D. Hu, J. Y. Yang, X. D. Cai, J. Yin, and C. F. Wu, “Studies on chemical constituents of leaf of Schisandra chinensis and inhibitory effect of schizandrin on activation of microglia induced by LPS,” Chinese Journal of Medicinal Chemistry, vol. 20, no. 2, pp. 110–115, 2010. View at Google Scholar
  12. Y. Ikeya, H. Taguchi, H. Sasaki, K. Nakajima, and I. Yoshioka, “13C NMR magnetic resonance spectroscopy of dibenzocyclooctadiene lignans,” Chemical & Pharmaceutical Bulletin, vol. 27, pp. 1383–1390, 1980. View at Google Scholar
  13. D. H. Kim, W. Y. Jung, S. J. Park et al., “Anti-amnesic effect of ESP-102 on Aβ142-induced memory impairment in mice,” Pharmacology Biochemistry and Behavior, vol. 97, no. 2, pp. 239–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Giacobini, “Cholinesterase inhibitors stabilize Alzheimer disease,” Neurochemical Research, vol. 25, no. 9-10, pp. 1185–1190, 2000. View at Google Scholar · View at Scopus
  15. A. Nordberg and A. L. Svensson, “Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology,” Drug Safety, vol. 19, no. 6, pp. 465–480, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Maurice, M. Hiramatsu, T. Kameyama, T. Hasegawa, and T. Nabeshima, “Cholecystokinin-related peptides, after systemic or central administration, prevent carbon monoxide-induced amnesia in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 269, no. 2, pp. 665–673, 1994. View at Google Scholar · View at Scopus
  17. X. F. Ji, X. X. Liu, Z. Wu, B. Z. Yang, L. H. Wang, and L. B. Zou, “Improving effects of extract of the husk of Xanthoceras sorbifolia Bunge on amyloid beta protein-induced learning and memory impairmant in animal models,” ShenYang Pharmaceutical University, vol. 24, pp. 232–237, 2007. View at Google Scholar
  18. T. Y. Chi, L. H. Wang, X. F. Ji et al., “Protective effects of Xanthoceraside on learning and memory impairmant induced by Aβ142 in mice,” Journal of China Medical University, vol. 38, pp. 734–736, 2009. View at Google Scholar
  19. A. M. Dong, “Anti-vascular dementia effects of Puerariae Isoflavone,” Shenyang Pharmaceutical University, p. 18, 2003. View at Google Scholar
  20. S. Qu, “Effects of Xanthoceraside on learning and memory impairment in mice induced by Aβ2535,” Shenyang Pharmaceutical University, p. 15, 2007. View at Google Scholar
  21. K. Yamada and T. Nabeshima, “Animal models of Alzheimer's disease and evaluation of anti-dementia drugs,” Pharmacology and Therapeutics, vol. 88, no. 2, pp. 93–113, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Harkany, J. Mulder, M. Sasvári et al., “N-methyl-D-aspartate receptor antagonist MK-801 and radical scavengers protect cholinergic nucleus basalis neurons against β-amyloid neurotoxicity,” Neurobiology of Disease, vol. 6, no. 2, pp. 109–121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Jhoo, H. C. Kim, T. Nabeshima et al., “β-Amyloid (1−42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex,” Behavioural Brain Research, vol. 155, no. 2, pp. 185–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Pepeu, L. Giovannelli, F. Casamenti, C. Scali, and L. Bartolini, “Amyloid β-peptides injection into the cholinergic nuclei: morphological, neurochemical and behavioral effects,” Progress in Brain Research, vol. 109, pp. 273–282, 1996. View at Google Scholar · View at Scopus
  25. S. A. Hitchcock, “Blood-brain barrier permeability considerations for CNS-targeted compound library design,” Current Opinion in Chemical Biology, vol. 12, no. 3, pp. 318–323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Y. Niu, Z. J. Bian, and Z. H. Ren, “The metabolic fate of schizandrol A and its distribution in the rat brain determined by thin layer chromatography,” Acta Pharmaceutica Sinica, vol. 18, no. 7, pp. 491–495, 1983. View at Google Scholar · View at Scopus
  27. T. T. Bao, G. F. Tu, G. T. Liu, R. H. Sun, and Z. Y. Song, “A comparison of the pharmacological actions of seven constituents isolated from fructus schizadrae (author's transl),” Acta Pharmaceutica Sinica, vol. 14, no. 1, pp. 1–7, 1979. View at Google Scholar · View at Scopus
  28. M. Dooley and H. M. Lamb, “Donepezil. A review of its use in Alzheimer's disease,” Drugs and Aging, vol. 16, no. 3, pp. 199–226, 2000. View at Google Scholar · View at Scopus
  29. S. Y. Xu, R. L. Bian, X. Chen et al., Pharmacology Experimental Methodology, Beijing, China, 3rd edition, 2005.
  30. B. Hunter, S. F. Zornetzer, M. E. Jarvik, and J. L. McGaugh, “Modulation of learning and memory: effects of drugs influencing neurotransmitters,” in Handbook of Psychopharmacology, L. L. Iversen, S. D. Iversen, S. H. Snyder et al., Eds., vol. 19, pp. 531–577, New York, NY, USA, 1988. View at Google Scholar
  31. R. Squitti, P. M. Rossini, E. Cassetta et al., “D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients,” European Journal of Clinical Investigation, vol. 32, no. 1, pp. 51–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. P. H. Reddy, “Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease,” Journal of Neurochemistry, vol. 96, no. 1, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Dumont and M. F. Beal, “Neuroprotective strategies involving ROS in Alzheimer disease,” Free Radical Biology and Medicine, vol. 51, pp. 1014–1026, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. X. J. Li, B. L. Zhao, G. T. Liu, and W. J. Xin, “Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations,” Free Radical Biology and Medicine, vol. 9, no. 2, pp. 99–104, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Liu, R. Yu, J. H. Wu, and H. M. Luo, “γ-schisandrin inhibits production of amyloid β-protein 42 in M146L cells,” Yaoxue Xuebao, vol. 41, no. 12, pp. 1136–1140, 2006. View at Google Scholar · View at Scopus
  36. L. Opletal, H. Sovová, and M. Bártlová, “Dibenzo[a, c]cyclooctadiene lignans of the genus Schisandra: importance, isolation and determination,” Journal of Chromatography B, vol. 812, no. 1-2, pp. 357–371, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. P. Wang, S. L. Raung, M. F. Hsu, and C. C. Chen, “Inhibition by gomisin C (a lignan from Schizandra chinensis) of the respiratory burst of rat neutrophils,” British Journal of Pharmacology, vol. 113, no. 3, pp. 945–953, 1994. View at Google Scholar · View at Scopus
  38. T. F. Slater, “Overview of methods used for detecting lipid peroxidation,” Methods in Enzymology, vol. 105, pp. 283–293, 1984. View at Google Scholar · View at Scopus
  39. M. J. Xu, G. J. Wang, H. T. Xie et al., “Determination of schizandrin in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies,” Journal of Chromatography B, vol. 828, no. 1-2, pp. 55–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Y. Cui and M. Z. Wang, “Metabolic transformation of schizandrin,” Acta Pharmaceutica Sinica, vol. 27, no. 1, pp. 57–63, 1992. View at Google Scholar · View at Scopus